Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Sci Rep ; 7(1): 6605, 2017 07 26.
Article in English | MEDLINE | ID: mdl-28747766

ABSTRACT

Several studies have shown an association of alcohol dependence with DNA methylation (DNAm), suggesting that environmentally-induced changes on epigenomic variation may play an important role in alcohol dependence. In the present study, we analysed genome-wide DNAm profiles of purified CD3+ T-cells from pre- and post-treatment alcohol dependent patients, as well as closely matched healthy controls. We identified 59 differentially methylated CpG sites comparing patients prior to treatment with healthy controls and were able to confirm 8 of those sites in additional analyses for differentially methylated regions. Comparing patients before and after a 3-week alcohol treatment program we revealed another unique set of 48 differentially methylated CpG sites. Additionally, we found that the mean global DNAm was significantly lower in patients prior to treatment compared to controls, but reverted back to levels similar to controls after treatment. We validated top-ranked hits derived from the epigenome-wide analysis by pyrosequencing and further replicated two of them in an independent cohort and confirmed differential DNAm of HECW2 and SRPK3 in whole blood. This study is the first to show widespread DNAm variation in a disease-relevant blood cell type and implicates HECW2 and SRPK3 DNAm as promising blood-based candidates to follow up in future studies.


Subject(s)
Alcoholism/pathology , CD3 Complex/analysis , DNA Methylation , T-Lymphocyte Subsets/pathology , Adult , Alcoholism/drug therapy , Epigenesis, Genetic/drug effects , Humans , Male , Middle Aged , T-Lymphocyte Subsets/chemistry
2.
Epigenetics ; 11(6): 456-63, 2016 Jun 02.
Article in English | MEDLINE | ID: mdl-27128683

ABSTRACT

Alcohol dependence is a severe disorder contributing substantially to the global burden of disease. Despite the detrimental consequences of chronic alcohol abuse and dependence, effective prevention strategies as well as treatment options are largely missing to date. Accumulating evidence suggests that gene-environment interactions, including epigenetic mechanisms, play a role in the etiology of alcohol dependence. A recent epigenome-wide study reported widespread alterations of DNA methylation patterns in alcohol dependent patients compared to control individuals. In the present study, we validate and replicate one of the top findings from this previous investigation in an independent cohort: the hypomethylation of GDAP1 in patients. To our knowledge, this is the first independent replication of an epigenome-wide finding in alcohol dependence. Furthermore, the AUDIT as well as the GSI score were negatively associated with GDAP1 methylation and we found a trend toward a negative association between GDAP1 methylation and the years of alcohol dependency, pointing toward a potential role of GDAP1 hypomethylation as biomarker for disease severity. In addition, we show that the hypomethylation of GDAP1 in patients reverses during a short-term alcohol treatment program, suggesting that GDAP1 DNA methylation could also serve as a potential biomarker for treatment outcome. Our data add to the growing body of knowledge on epigenetic effects in alcohol dependence and support GDAP1 as a novel candidate gene implicated in this disorder. As the role of GDAP1 in alcohol dependence is unknown, this novel candidate gene should be followed up in future studies.


Subject(s)
Alcoholism/genetics , DNA Methylation , Nerve Tissue Proteins/genetics , Adult , Alcoholism/blood , Alcoholism/therapy , Biomarkers/blood , Case-Control Studies , Epigenesis, Genetic , Humans , Male , Middle Aged , Treatment Outcome
3.
Mov Disord ; 26(13): 2335-42, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21989859

ABSTRACT

The objective of this research was to evaluate a possible endophenotype in leucine-rich repeat kinase 2 (LRRK2)-associated Parkinson's disease (PD). Ten symptomatic LRRK2 patients, 24 sporadic Parkinson's disease patients as well as 10 asymptomatic LRRK2 mutation carriers and 29 matched healthy controls underwent comprehensive clinical assessments with respect to motor and non-motor symptoms. Transcranial sonography and magnetic resonance imaging (voxel-based morphometry [VBM]) were assessed to evaluate morphological imaging characteristics. LRRK2 patients had an earlier onset of motor symptoms and a more benign phenotype of motor and non-motor characteristics compared to sporadic Parkinson's disease patients. However, depression scores were higher in LRRK2 patients. No clinical differences were found regarding motor and non-motor symptoms in asymptomatic LRRK2 mutation carriers in comparison to controls. Transcranial sonography showed hyperechogenicity of the substantia nigra in both patients' cohorts as well as in asymptomatic LRRK2 mutation carriers. Voxel-based morphometry revealed increased gray matter volume of the cerebellum and precentral gyrus in LRRK2 patients and of the cuneus in asymptomatic LRRK2 mutation carriers. In contrast, we found decreased basal ganglia gray matter volume in LRRK2 patients compared to controls. Increased gray matter volume of different anatomical structures associated with motor loops in LRRK2 patients and asymptomatic LRRK2 mutation carriers compared to age-matched sporadic Parkinson's disease patients and controls might indicate compensatory mechanism in LRRK2 mutation carriers due to motor network plasticity not only in the symptomatic stage of the disease but even in the premotor phase. Substantia nigra hyperechogenicity in yet unaffected LRRK2 mutation carriers indicates morphologic alterations in an asymptomatic stage of disease.


Subject(s)
Parkinson Disease/enzymology , Parkinson Disease/genetics , Protein Serine-Threonine Kinases/genetics , Adult , Aged , Aged, 80 and over , Cohort Studies , Genotype , Heterozygote , Humans , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Middle Aged , Mutation/genetics , Neuropsychological Tests , Parkinson Disease/pathology , Severity of Illness Index , Substantia Nigra/enzymology , Ultrasonography, Doppler, Transcranial
4.
Neurobiol Aging ; 32(9): 1599-606, 2011 Sep.
Article in English | MEDLINE | ID: mdl-19897277

ABSTRACT

Much effort has been put in the identification of risk factors and pre-motor markers for Parkinson's disease (PD). In contrast to many of the pre-motor markers, SN hyperechogenicity (SN+) assessed by transcranial sonography (TCS) has been found to be conclusive for vulnerability for PD. In two centers in Germany 1204 individuals ≥50 years without the diagnosis of PD were recruited and the prevalence and relation of SN+ to a range of pre-motor markers was evaluated. SN+ was detected in 193 (16.0%) of 1204 subjects. Hyposmia (25.4%) was the most frequent sign in the cohort, followed by the occurrence of slight motor deficits. Male gender, positive family history of PD as possible risk factors and the pre-motor markers slight parkinsonian signs, one-sided reduced arm swing, and hyposmia were found to be significantly associated with SN+. The number of subjects who had more than one marker was significantly larger in the SN+ subgroup than in the non-hyperechogenic group (9.2% vs. 2.1%). Most of the discussed markers for PD seem to be unspecific with older age, but related to SN+. Co-occurrence of these markers is more probable in SN+ subjects. These findings may have implications for the design of high-risk cohorts for PD.


Subject(s)
Parkinson Disease/diagnostic imaging , Parkinson Disease/epidemiology , Substantia Nigra/diagnostic imaging , Ultrasonography, Doppler, Transcranial/methods , Ultrasonography, Doppler, Transcranial/standards , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , Parkinson Disease/physiopathology , Prospective Studies , Risk Factors , Substantia Nigra/pathology , Substantia Nigra/physiopathology
5.
Mov Disord ; 25(10): 1464-9, 2010 Jul 30.
Article in English | MEDLINE | ID: mdl-20629151

ABSTRACT

Enlarged substantia nigra hyperechogenicity (SN+) assessed by transcranial sonography (TCS) may be associated with Parkinson's disease (PD) risk markers such as impaired motor performance and hyposmia. The aim of this multicenter cross-sectional study was to define the association between SN+ and these risk markers in a large population older than 50 years without the diagnosis of PD. In three centers (Tuebingen, Homburg, and Innsbruck), 1,839 individuals were examined. The echostatus of the SN was assessed by TCS, motor performance by the Unified Parkinson's Disease Rating Scale (UPDRS) motor score, and olfactory function with Sniffin' Sticks. From the 1,603 subjects included in the analysis, 16.2% were SN+, 23.0% scored above zero in the UPDRS motor section, and 28.0% were hyposmic as defined by less than 75% correctly classified Sniffin' Sticks. SN+ was associated with a UPDRS motor score above zero (OR 1.45, 95% CI 1.08-1.96) and with a lower odor identification capability (OR 1.48, 95% CI 1.12-1.96). The combination of these two features (OR 1.98, 95% CI 1.25-3.15) and UPDRS motor scores >or=3 lead to higher OR. It is concluded that SN+, impaired motor performance, and hyposmia are frequently observed in the elderly and in isolation are unspecific and of limited use to predict a subject's risk for PD. Whether the association of SN+ with both impaired motor performance and hyposmia as seen in this study predicts an increased risk for the development of PD needs to be evaluated in the follow-up investigations.


Subject(s)
Aging/pathology , Olfaction Disorders/pathology , Olfaction Disorders/physiopathology , Psychomotor Performance/physiology , Substantia Nigra/pathology , Aged , Aged, 80 and over , Austria , Cohort Studies , Female , Germany , Humans , Logistic Models , Male , Middle Aged , Neurologic Examination , Substantia Nigra/diagnostic imaging , Ultrasonography, Doppler, Transcranial/methods
6.
Alzheimers Dement ; 6(1): 70-4, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20129321

ABSTRACT

Cognitive decline and dementia are present in about 50% of patients with progressive supranuclear palsy (PSP). Based on the known involvement of the cholinergic system in PSP patients, and because rivastigmine, in contrast to other cholinesterase inhibitors, inhibits both acetylcholinesterase and butyrylcholinesterase, we discuss clinical observations of five patients suffering from PSP and dementia who were all treated with rivastigmine over a period of 3 to 6 months. We found a slight improvement in specific cognitive function that may justify further controlled studies. A calculation of sample size revealed that a study on the effect of rivastigmine in PSP should include about 31 patients to detect a significant effect. In subtests, meaningful results can be obtained with even lower numbers (five patients for a verbal fluency test, and 14 patients for a logical memory task).


Subject(s)
Dementia/drug therapy , Neuroprotective Agents/therapeutic use , Phenylcarbamates/therapeutic use , Supranuclear Palsy, Progressive/drug therapy , Aged , Behavioral Symptoms/drug therapy , Behavioral Symptoms/etiology , Cognition Disorders/drug therapy , Cognition Disorders/etiology , Dementia/complications , Female , Humans , Male , Neuropsychological Tests , Psychiatric Status Rating Scales , Rivastigmine , Supranuclear Palsy, Progressive/complications
7.
Lancet Neurol ; 7(5): 417-24, 2008 May.
Article in English | MEDLINE | ID: mdl-18394965

ABSTRACT

BACKGROUND: Increased echogenicity of the substantia nigra (SN), as determined by transcranial sonography (TCS), is characteristic of idiopathic Parkinson's disease (iPD). The results of initial retrospective studies indicate that this ultrasound sign is specific for iPD and can help to differentiate it from atypical parkinsonian syndromes (aPS); however, these early studies were done in patients with later disease stages and known clinical diagnosis. We aimed to determine the diagnostic value of TCS in the early stages of parkinsonian syndromes, when the clinical symptoms often do not enable a definite diagnosis to be made. METHODS: 60 patients who presented with the first, but still unclear, clinical symptoms of parkinsonism had TCS in this prospective blinded study. Investigators were blinded to the results of the clinical investigations, the ultrasound findings, and the diagnosis at time of investigation. The patients were followed-up every 3 months for 1 year to assess and re-evaluate the clinical symptoms. The patients in whom a clinical diagnosis could not be made with certainty were investigated with raclopride PET or dopamine transporter single-photon emission computed tomography (SPECT), or both. FINDINGS: A clinical diagnosis of parkinsonism could not be established at baseline in 38 patients. At 12 months, 39 patients were clinically categorised as having iPD. Compared with endpoint diagnosis, the sensitivity of TCS at baseline was 90%7% and the specificity was 82.4%; the positive predictive value of TCS for iPD was 92.9% and the classification accuracy was 88.3%. INTERPRETATION: TCS is an easy to implement, non-invasive, and inexpensive technique that could help in the early differential diagnosis of parkinsonian syndromes. The routine use of TCS in the clinic could enable disease-specific therapy to be started earlier. FUNDING: Michael J Fox Foundation for Parkinson's Research.


Subject(s)
Parkinson Disease/diagnostic imaging , Ultrasonography, Doppler, Transcranial , Adult , Aged , Aged, 80 and over , Basal Ganglia/diagnostic imaging , Diagnosis, Differential , Double-Blind Method , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multiple System Atrophy/diagnostic imaging , Prospective Studies , Retrospective Studies , Sensitivity and Specificity , Substantia Nigra/diagnostic imaging , Time Factors
8.
Mov Disord ; 23(8): 1184-7, 2008 Jun 15.
Article in English | MEDLINE | ID: mdl-18442125

ABSTRACT

Evidence for tissue iron deficiency in restless legs syndrome (RLS) is limited to the substantia nigra (SN). Using MRI, we assessed T2 values of various brain regions in 6 RLS patients and 19 controls and correlated them with sonographically assessed SN echogenicity. Both neuroimaging features are supposed to correlate with tissue iron content. Mean T2 values of all regions were higher in patients (2.9-7.8%), though significantly increased only in four regions; the mean T2 over all voxels was higher in patients (5.1%, P < 0.001) and correlated inversely with SN echogenicity (r = -0.61, P < 0.001). This indicates multiregional (global) brain iron deficiency in RLS and proposes SN echogenicity as a potential morphological marker for brain iron status. (c) 2008 Movement Disorder Society.


Subject(s)
Brain/pathology , Iron Deficiencies , Magnetic Resonance Imaging , Restless Legs Syndrome/pathology , Aged , Echoencephalography , Female , Ferritins/blood , Humans , Male , Middle Aged , Reference Values , Substantia Nigra/pathology
9.
Sleep Med ; 9(7): 782-9, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18024170

ABSTRACT

BACKGROUND AND PURPOSE: Using transcranial B-mode sonography (TCS), the first morphological marker for restless legs syndrome (RLS), hypoechogenicity of the substantia nigra (SN) has been found. The aim of this study was to validate SN hypoechogenicity as a morphological marker for RLS in a large patient cohort and to investigate further RLS-associated brain abnormalities using TCS. METHODS: One hundred forty-three RLS patients (37 with symptomatic RLS) and 45 controls, matched for age and gender, underwent TCS by an experienced and independent rater who was blinded to clinical data. RESULTS: The basal ganglia, ventricular system and cerebral lobes showed no RLS-specific abnormalities. SN hypoechogenicity correlated with a family history of RLS (p<0.001) and showed good sensitivity (82%), specificity (83%) and positive predictive value (94%). Red nucleus hyperechogenicity and brainstem raphe (BR) hypoechogenicity were more prevalent in RLS than in controls (both p<0.001) and correlated with reported periodic limb movements and depression, respectively (both p<0.001). Seventy-six percent of the patients (7% of controls) showed a co-occurrence of two or more sonographical abnormalities; 60% of symptomatic RLS patients showed the same sonographic features as the majority of RLS patients. CONCLUSIONS: TCS is a useful additional tool for diagnosing RLS and RLS-related disorders that demonstrate various brainstem abnormalities.


Subject(s)
Brain Stem/diagnostic imaging , Echoencephalography , Restless Legs Syndrome/diagnostic imaging , Adult , Aged , Aged, 80 and over , Dominance, Cerebral/physiology , Female , Humans , Male , Middle Aged , Polysomnography , Raphe Nuclei/diagnostic imaging , Red Nucleus/diagnostic imaging , Substantia Nigra/diagnostic imaging , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...